Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Comparative E-Cadherin Digital Expression Analysis in HPV and non-HPV Related Squamous Cell Carcinoma of the Oral Cavity

ARISTEIDIS CHRYSOVERGIS, VASILEIOS PAPANIKOLAOU, NICHOLAS MASTRONIKOLIS, DESPOINA SPYROPOULOU, MARIA ADAMOPOULOU, EVANGELOS TSIAMBAS, DIMITRIOS PESCHOS, VASILEIOS RAGOS and EFTHYMIOS KYRODIMOS
Anticancer Research January 2021, 41 (1) 163-167; DOI: https://doi.org/10.21873/anticanres.14761
ARISTEIDIS CHRYSOVERGIS
11ST ENT Department, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VASILEIOS PAPANIKOLAOU
11ST ENT Department, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICHOLAS MASTRONIKOLIS
2ENT Department, Medical School, University of Patras, Patras, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DESPOINA SPYROPOULOU
3Department of Radiation Oncology, Medical School, University of Patras, Patras, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA ADAMOPOULOU
4Department of Biomedical Sciences, University of West Attica, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EVANGELOS TSIAMBAS
5Department of Cytology, 417 VA Hospital (NIMTS), Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tsiambasecyto@yahoo.gr
DIMITRIOS PESCHOS
6Department of Physiology, Medical School, University of Ioannina, Ioannina, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VASILEIOS RAGOS
7Dept of Maxillofacial, Medical School, University of Ioannina, Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EFTHYMIOS KYRODIMOS
11ST ENT Department, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Oral squamous cell carcinoma (OSCC) demonstrates aggressive biological behavior in subgroups of patients with specific molecular characteristics. Concerning metastatic potential, disruption of cell to cell adhesion is a critical event in epithelial malignancies including OSCC. Our aim was to investigate the role of E-Cadherin expression in OSCC patients as a valuable protein marker. Materials and Methods: Fifty (n=50) tissue sections derived from primary OSCCs were analyzed by implementing an immunohistochemistry (IHC) assay based on a proper anti-E-cadherin antibody. Digital image analysis was also implemented for an objective evaluation of the corresponding protein expression levels. Results: E-cadherin altered expression (low to negative) was observed in 34/50 (68%) cases, whereas the rest (16/50-32%) demonstrated normal (high to moderate) expression. E-Cadherin abnormal expressionwas associated with the stage of the examined malignancies (p=0.023), whereas no significant correlations with grade, gender, smoking status or human papilloma virus (HPV) history were observed. Conclusion: E-Cadherin down regulation is frequently observed in OSCC and is correlated to a progressively aggressive phenotype of the malignancy in the corresponding patients (advanced stage), but it seems that the impact of HPV persistent infection on these patients is not a critical parameter.

Key Words:
  • Carcinoma
  • oral
  • e-cadherin
  • HPV
  • immunohistochemistry
  • analysis

Typically, oral squamous cell carcinoma (OSSC) is characterized by an aggressive phenotype including poor prognosis, moderate response rates to chemo-radiotherapy and targeted therapeutic agents, such as monoclonal antibodies (1, 2). Pre-malignant histology in oral epithelia recognizes different levels of leukoplakia (3). Molecular analyses in solid malignancies -including OSCC- have shown that deregulation and functional loss in critical molecules -such as cadherins and proto-cadherins- that stabilize intra-epithelial cells conjunctions are responsible for the aggressive biological behaviour in these patients (4). Cadherins play a significant role in prohibiting metastatic potential as calcium dependent protein family glycoproteins that secure cell to cell adhesion. Based on their structural nature, they consist of three parts including an extracellular domain, a bridge membrane-cytoplasm region and a cytoplasmic end (5). Concerning their functional status, they are involved in tissue differentiation, whereas a suppressor activity in other genes has been also detected. The e-cadherin/catenin complex affects signal transduction to the nucleus by activating the c-Src factor during epithelial cell adhesion, also modifying actin-filament assembly (6). The E-cadherin gene (CDH1) is located on chromosome 16 (16q22.1) encoding for a calcium-dependent cell-cell adhesion glycoprotein. Mechanisms of CDH1 gene deregulation in carcinomas include somatic point mutations, deletions or promoter methylation leading to a progressive loss of its protein expression (7). In the current study, we focused on evaluating the E-cadherin protein expression levels, by implementing an objective process (digital image analysis) in a series of OSCC tissue sections and correlating them to their corresponding clinico-histological parameters.

Materials and Methods

Study group. In order to explore the role of E-cadherin protein aberrations in OSCC, fifty (n=50) archival, formalin-fixed, and paraffin-embedded tissue specimens of histologically confirmed primary OSCCs were used. It should be mentioned that all the corresponding histopathological material was derived from surgical operations at the beginning of the diagnosis of the disease as a primary malignancy and not from a local recurrence. The hospital ethics committee consented to the use of these tissues in Hippocration Hospital, University of Athens, Athens, Greece, for research purposes (Reference ID research protocol: 2226/09.09.2018), according to World Medical Association Declaration of Helsinki guidelines (2008, revised 2014). The tissue samples were fixed in 10% neutral-buffered formalin. Hematoxylin and eosin (H&E)-stained slides of the corresponding samples were reviewed for confirmation of the histopathological diagnoses. All lesions were classified according to the histological typing and staging criteria of the World Health Organization (WHO) Pathology Series (8). The majority of the examined lesions were derived from the tongue (n=46), whereas the rest of them were derived from the retromolar trigone (1), the floor of the mouth (n=2), and the buccal mucosa (n=1). Concerning HPV DNA status (positivity or not), the corresponding information was derived from the patients’ medical records. Among them, eighteen (n=18) cases were recognized as HPV DNA-positive. HPV 16/31/53 high-risk (HR) subtypes were detected mainly by analyzing the corresponding cases. Clinicopathological data of the examined cases are demonstrated in Table I.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Clinicopathological parameters and total E-cadherin IHC results.

Antibodies and immunohistochemistry assay (IHC). For protein anlyses we selected and applied in the corresponding OSCC tissue sections ready-to-use anti-E-cadherin (Clone NCH-38 Dako, Glostrup, Denmark) mouse monoclonal antibody. The IHC protocol for the antigen was based on 3 μm serial tissue sections. The slides were deparaffinized and rehydrated. The NBA kit (Zymed-InVitrogen, San Fransisco, CA, USA) was used. Blocking solution was applied to all slides for 10min, followed by incubation for 1 h using the monoclonal antibody at room temperature (25°C). Following incubation with the secondary antibody for 10 min, diaminobenzidine-tetrahydrocloride-DAB (0.03%) containing 0.1% hydrogen peroxide was applied as a chromogen and incubated for 5 min. Immunostained tissue sections were counterstained, dehydrated and cover-slipped. For negative control slides, the primary antibody was omitted. IHC protocol was performed by the use of an automated staining system (I 6000 Biogenex, CA, USA). Predominantly membranous and cytoplasmic staining was considered acceptable for the marker, according to manufacturers’ data sheet (Figure 1a-b). Normal appearing oral epithelia expressing the protein were used as the control group.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

E-cadherin differential expression patterns in OSCC using IHC (a) Note the membranous ring-like dense dark staining pattern (high expression). (b) Loss of protein expression (negative). (c-e) Digital image analysis procedure for evaluation of protein expression. (DAB chromogen, original magnification 100×).

Digital image analysis assay (DIA). E-cadherin protein expression levels were evaluated quantitatively by calculating the corresponding staining intensity levels (densitometry evaluation) in the stained malignant tissues. We performed DIA using a semi-automated system (Microscope: CX-31, Olympus, Melville, NY, USA; Digital camera: Sony, Tokyo, Japan; Software: NIS-Elements Software AR v3.0, Nikon Corp, Tokyo, Japan). Areas of interest per tissue section were identified (5 optical fields at ×400 magnification) and filed in a digital database as snapshots. Measurements were performed by implementing a specific macro (mainly membranous and sub-membrane cytoplasmic expression for tumor cells, according to the manufacturer’s datasheet for mouse monoclonal anti-E-cadherin, Clone NCH-38 Dako). Based on an algorithm, normal tissue sections (controls) were measured independently and compared to the corresponding values in malignant tissue sections. A broad spectrum of continuous grey scale values (0-255) at the RedGreenBlue (RGB) analysis was available for discriminating different protein expression levels (Figure 1c-e). Immunostaining intensity values decreasing to 0 represent a progressive over expression of the marker, whereas values increasing to 255 show a progressive loss of its staining intensity. Total results and DIA values are demonstrated in Table I.

Statistical analysis. Descriptive statistics were performed. In order to identify statistical significance, correlations between variables such as protein expression levels and clinicopathological parameters including gender, tumor grade and stage were performed using the Pearson Chi square test (χ2), estimated along with its 99%CI and Spearman coefficient [SPSS v20 (SPSS Inc, Chicago, IL, USA)]. Two-tailed p-values ≤0.05 were considered statistically significant. Results and p-Values are described in Table I.

Results

According to IHC evaluation guidelines, the examined cases demonstrated different E-cadherin expression levels with a prominent membrane and also sub-membrane cytoplasmic pattern. Stratification regarding the marker’s expression was based on grouping the extracted staining intensity levels in negative, low, moderate and high values. E-cadherin altered expression (low to negative) was observed in 34/50 (68%) cases, whereas the rest of them (16/50-32%) demonstrated normal (high to moderate) expression. E-Cadherin abnormal expression was associated with the stage of the examined malignancies (p=0.023). A progressive loss of the protein expression was observed, especially in advanced stage tissue sections. No statistical significance was observed correlating overall E-cadherin expression to the grade (p=0.421), gender (p=0.564), smoking status (p=0.522) or HPV-positive/negative history (p=0.227), respectively.

Discussion

Malignant transformation of normal oral squamous epithelia is a multi-step process based on pro- and neoplastic lesions in different grades of dysplasia under the term oral leukoplakia (9, 10). In these lesions and also progressively in OSCC, a reduction of E-cadherin activity -as a significant adhesion molecule in epithelial tissue homeostasis has been observed (11, 12). Additionally, E-cadherin deregulation seems to be combined with other critical molecules in these early stages of oral carcinogenesis, including β-catenin, Desmoglein-3/γ-catenin, laminin, collagen IV, Twist, and also p53 (13-16). Concerning solid malignancies -such as breast and colorectal adenocarcinomas- E-cadherin down regulation -leading to a progressive loss of expression- is correlated to an aggressive phenotype (advanced stage and poor prognosis) (17, 18). Interestingly, in these malignancies modified expression patterns (membranous or cytoplasmic) have been observed.

In our protein analysis, low level or loss of the marker’s expression was observed in a significant number of the examined malignant tissues and correlated to the stage of the examined cases. Another study has shown similar association while focusing on lymph node metastasis (N stage) leading to poor prognosis, but not at the mRNA level in OSCC patients (19). Additionally, another study co-analyzed E-cadherin and vimentin expression levels and patterns in order to find potential correlation in OSCC patients regarding epithelial-mesenchymal transition (EMT). They observed that both were strongly associated with lymph node metastasis (N stage). Interestingly, E-cadherin was correlated to advanced stages of the examined cases and for this reason should be considered a valuable tool for predicting OSCC patient outcome (20). Concerning the impact of HPV-persistent infection in E-cadherin inactivation and modified expression, there are controversial aspects (21). Some studies report E-cadherin reduced activity mediated by E6/E7 HPV oncoproteins that are responsible for PIR gene overexpression in epithelial oral and cervical cell cultures (22). Interestingly, a study group showed that targeted agents –applied for tyrosine-kinase inhibition of growth factors receptors, such as nilotinib, dasatinib, erlotinib, and gefitinib- led to E-cadherin/β-catenin complex activation in both HPV16-positive and HPV16-negative cells in vitro and this could be a future strategy in HNSCC therapeutic regimens, including OSCCs (23).

In conclusion, our study showed that E-cadherin down regulation is frequently observed in OSCCs and correlated to a progressively aggressive phenotype of the malignancy in the corresponding patients (advanced stage). However, it seems that the impact of HPV persistent infection on these patients is not a critical parameter. As E-cadherin activation and stabilization is a crucial parameter acting as a resistant mechanism to metastases in malignancies, novel targeted agents could provide support in the tumor microenvironment, preventing a potentially aggressive biological phenotype in sub-groups of OSCC patients.

Footnotes

  • Authors’ Contributions

    Aristeidis Chrysovergis, Vasileios Papanikolaou: researchers, statistical analysis; Nicholas Mastronikolis: academic advisor, Despoina Spyropoulou, Maria Adamopoulou: academic advisor; Evangelos Tsiambas: researcher, manuscript writing; Dimitrios Peschos, Vasileios Ragos: academic advisor; Efthymios Kyrodimos: researcher, manuscript writing.

  • Conflicts of Interest

    The Authors declare no conflicts of interest regarding this study.

  • Received October 11, 2020.
  • Revision received November 12, 2020.
  • Accepted November 20, 2020.
  • Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Mashberg A
    : Diagnosis of early oral and oropharyngeal squamous carcinoma: obstacles and their amelioration. Oral Oncol 36(3): 253-255, 2000. PMID: 10793326. DOI: 10.1016/s1368-8375(00)00006-3
    OpenUrlCrossRefPubMed
  2. ↵
    1. Jin C,
    2. Jin Y,
    3. Wennerberg J,
    4. Annertz K,
    5. Enoksson J and
    6. Mertens F
    : Cytogenetic abnormalities in 106 oral squamous cell carcinomas. Cancer Genet Cytogen 164: 44-53, 2006. PMID: 16364762. DOI: 10.1016/j.cancergencyto.2005.06.008
    OpenUrlCrossRefPubMed
  3. ↵
    1. Warnakulasuriya S,
    2. Reibel J,
    3. Bouquot J and
    4. Dabelsteen ES
    : Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 37(3): 127-133, 2008. PMID: 18251935. DOI: 10.1111/j.1600-0714.2007.00584.x
    OpenUrlCrossRefPubMed
  4. ↵
    1. Pancho A,
    2. Aerts T,
    3. Mitsogianis MD and
    4. Seuntjens E
    : Protocadherins at the crossroad of signalling pathways. Front Mol Neurosci 13: 117-124, 2020. PMID: 32694982. DOI: 10.3389/fnmol.2020.00117
    OpenUrlCrossRefPubMed
  5. ↵
    1. Huels DJ,
    2. Ridgway RA,
    3. Radulescu S,
    4. Leushacke M,
    5. Campbell AD,
    6. Biswas S,
    7. Leedham S,
    8. Serra S,
    9. Chetty R,
    10. Moreaux G,
    11. Parry L,
    12. Matthews J,
    13. Song F,
    14. Hedley A,
    15. Kalna G,
    16. Ceteci F,
    17. Reed KR,
    18. Meniel VS,
    19. Maguire A,
    20. Doyle B,
    21. Söderberg O,
    22. Barker N,
    23. Watson A,
    24. Larue L,
    25. Clarke AR and
    26. Sansom OJ
    : E-cadherin can limit the transforming properties of activating β-catenin mutations. EMBO J 34(18): 2321-2333, 2015. PMID: 26240067. DOI: 10.15252/embj.201591739
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Gottardi CJ,
    2. Wong E and
    3. Gumbiner BM
    : E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in adhesion-independent manner. J Cell Biol 153: 1049-1060, 2001. PMID: 11381089. DOI: 10.1083/jcb.153.5.1049
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Braungart E,
    2. Schumacher C,
    3. Hartman E,
    4. Nekarda H,
    5. Becker KF,
    6. Höfler H and
    7. Atkinson MJ
    : Functional loss of E-cadherin and cadherin-11 alleles on chromosome 16q22 in colonic cancer. J Pathol 187: 530-534, 1999. PMID: 10398117. DOI: 10.1002/(SICI)1096-9896(199904)187
    OpenUrlCrossRefPubMed
  8. ↵
    1. Barnes L,
    2. Eveson JW,
    3. Reichart P and
    4. Sidransky D
    : Pathology and Genetics: Head and Neck Tumours; WHO IARC Press: Lyon, France, pp. 118-130, 2005.
  9. ↵
    1. Van der Wall I
    : Potentially malignant disorders of the oral and oropharyngeal mucosa: terminology, classification and present concepts of management. Oral Oncol 45: 317-323, 2009. PMID: 18674954. DOI: 10.1016/j.oraloncology.2008.05.016
    OpenUrlCrossRefPubMed
  10. ↵
    1. Warnakulasuriya S,
    2. Reibel J,
    3. Bouquot J and
    4. Dabelsteen E
    : Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 37: 127-133, 2008. PMID: 18251935. DOI: 10.1111/j.1600-0714.2007.00584.x
    OpenUrlCrossRefPubMed
  11. ↵
    1. von Zeidler SV,
    2. de Souza Botelho T,
    3. Mendonça EF and
    4. Batista AC
    : E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: a retrospective cohort study. BMC Cancer 14: 972-976, 2014. PMID: 25518919. DOI: 10.1186/1471-2407-14-972
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hashimoto T,
    2. Soeno Y,
    3. Maeda G,
    4. Taya Y,
    5. Aoba T,
    6. Nasu M,
    7. Kawashiri S and
    8. Imai K
    : Progression of oral squamous cell carcinoma accompanied with reduced E-cadherin expression but not cadherin switch. PLoS One 7(10): e47899-906, 2012. PMID: 23110125. DOI: 10.1371/journal.pone.0047899
    OpenUrlCrossRefPubMed
  13. ↵
    1. Kaur J,
    2. Sawhney M,
    3. DattaGupta S,
    4. Shukla NK,
    5. Srivastava A,
    6. Walfish PG and
    7. Ralhan R
    : Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression. PLoS One 8(6): e67361-65, 2013. PMID: 23840677. DOI: 10.1371/journal.pone.0067361
    OpenUrlCrossRefPubMed
    1. Kyrodimou M,
    2. Andreadis D,
    3. Drougou A,
    4. Amanatiadou EP,
    5. Angelis L,
    6. Barbatis C,
    7. Epivatianos A and
    8. Vizirianakis IS
    : Desmoglein-3/γ-catenin and E-cadherin/β-catenin differential expression in oral leukoplakia and squamous cell carcinoma. Clin Oral Invest 18: 199-210, 2014. PMID: 23430339. DOI: 10.1007/s00784-013-0937-z
    OpenUrlCrossRefPubMed
    1. García AS,
    2. Hernández MMA,
    3. Sánchez EF,
    4. Gonzales RJ,
    5. Villardón PG,
    6. Hernandéz JJC and
    7. Sopelana AB
    : E-cadherin, laminin and collagen IV expression in the evolution from dysplasia to oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 11(2): E100-105, 2006. PMID: 16505783.
    OpenUrlPubMed
  14. ↵
    1. Fan C,
    2. Wang T,
    3. Cheng Y,
    4. Jiang SS,
    5. Cheng C,
    6. Lee AY and
    7. Kao T
    : Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma. J Cancer Res Clin Oncol 139: 1735-1744, 2013. PMID: 23990016. DOI: 10.1007/s00432-013-1499-9
    OpenUrlCrossRefPubMed
  15. ↵
    1. Margan MM,
    2. Cimpean AM,
    3. Ceausu AR and
    4. Raica M
    : Differential expression of E-cadherin and P-cadherin in breast cancer molecular subtypes. Anticancer Res 40(10): 5557-5566, 2020. PMID: 32988879. DOI: 10.21873/anticanres.14568
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Bendardaf R,
    2. Sharif-Askari FS,
    3. Sharif-Askari NS,
    4. Syrjänen K and
    5. Pyrhönen S
    : Cytoplasmic E-cadherin expression is associated with higher tumour level of VEGFA, lower response rate to irinotecan-based treatment and poorer prognosis in patients with metastatic colorectal cancer. Anticancer Res 39(4): 1953-1957, 2019. PMID: 30952738. DOI: 10.21873/anticanres.13305
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. López-Verdín S,
    2. Martínez-Fierro ML,
    3. Garza-Veloz I,
    4. Zamora-Perez A,
    5. Grajeda-Cruz J,
    6. González-González R,
    7. Molina-Frechero N,
    8. Arocena-Sutz M and
    9. Bologna-Molina R
    : E-Cadherin gene expression in oral cancer: Clinical and prospective data. Med Oral Patol Oral Cir Bucal 24(4): e444-455, 2019. PMID: 31256188. DOI: 10.4317/medoral.23029
    OpenUrlCrossRefPubMed
  18. ↵
    1. Zhou J,
    2. Tao D,
    3. Xu Q,
    4. Gao Z and
    5. Tang D
    : Expression of E-Cadherin and vimentin in oral squamous cell carcinoma. Int J Clin Exp Pathol 8(3): 3150-3154, 2015. PMID: 26045832.
    OpenUrlPubMed
  19. ↵
    1. Ottria L,
    2. Candotto V,
    3. Cura F,
    4. Baggi L,
    5. Arcuri C,
    6. Nardone M,
    7. Gaudio RM,
    8. Gatto R,
    9. Spadari F and
    10. Carinci F
    : HPV acting on E-cadherin, p53 and p16: Literature review. J Biol Regul Homeost Agents 32(2): 73-79, 2018. PMID: 29460521.
    OpenUrlPubMed
  20. ↵
    1. Carrillo D,
    2. Muñoz JP,
    3. Huerta H,
    4. Leal G,
    5. Corvalán A,
    6. León O,
    7. Calaf GM,
    8. Urzúa U,
    9. Boccardo E,
    10. Tapia JC and
    11. Aguayo F
    : Upregulation of PIR gene expression induced by human papillomavirus E6 and E7 in epithelial oral and cervical cells. Open Biol 7(11): 170111-170120, 2017. PMID: 29118270. DOI: 10.1098/rsob.170111
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kramer B,
    2. Hock C,
    3. Schultz JD,
    4. Lammert A,
    5. Kuhlin B,
    6. Birk R,
    7. Hörmann K and
    8. Aderhold C
    : Impact of small molecules on β-catenin and E-cadherin expression in HPV16-positive and-negative squamous cell carcinomas. Anticancer Res 37(6): 2845-2852, 2017. PMID: 28551620. DOI: 10.21873/anticanres.11636
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (1)
Anticancer Research
Vol. 41, Issue 1
January 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparative E-Cadherin Digital Expression Analysis in HPV and non-HPV Related Squamous Cell Carcinoma of the Oral Cavity
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Comparative E-Cadherin Digital Expression Analysis in HPV and non-HPV Related Squamous Cell Carcinoma of the Oral Cavity
ARISTEIDIS CHRYSOVERGIS, VASILEIOS PAPANIKOLAOU, NICHOLAS MASTRONIKOLIS, DESPOINA SPYROPOULOU, MARIA ADAMOPOULOU, EVANGELOS TSIAMBAS, DIMITRIOS PESCHOS, VASILEIOS RAGOS, EFTHYMIOS KYRODIMOS
Anticancer Research Jan 2021, 41 (1) 163-167; DOI: 10.21873/anticanres.14761

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Comparative E-Cadherin Digital Expression Analysis in HPV and non-HPV Related Squamous Cell Carcinoma of the Oral Cavity
ARISTEIDIS CHRYSOVERGIS, VASILEIOS PAPANIKOLAOU, NICHOLAS MASTRONIKOLIS, DESPOINA SPYROPOULOU, MARIA ADAMOPOULOU, EVANGELOS TSIAMBAS, DIMITRIOS PESCHOS, VASILEIOS RAGOS, EFTHYMIOS KYRODIMOS
Anticancer Research Jan 2021, 41 (1) 163-167; DOI: 10.21873/anticanres.14761
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tissue Prognostic Markers for Clear Cell Renal Cell Carcinoma Tumor-stroma Interaction: Impact on TNM Staging Parameters
  • CA9-Positive Keloid Fibroblasts: Modulator of Local Inflammation Induced by the Hypoxic and Glycolysis-enhanced Microenvironment
  • Predictive Factors for Multiple Metastases of Clear-cell Renal Cell Carcinoma
Show more Experimental Studies

Similar Articles

Keywords

  • carcinoma
  • oral
  • E-cadherin
  • HPV
  • immunohistochemistry
  • analysis
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire